Findings in Congenital Heart Disease Reported from Children's Hospital of Nanjing Medical University (Milrinone for the treatment of heart failure caused by severe Pneumonia in children with congenital heart disease: a meta-analysis).

A meta-analysis conducted by researchers at the Children's Hospital of Nanjing Medical University evaluated the effects and safety of milrinone for the treatment of heart failure caused by severe pneumonia in children with congenital heart disease (CHD). The analysis included eight randomized controlled trials involving 680 CHD children. The results showed that milrinone was beneficial in improving clinical symptoms and cardiac function, with a higher total effective rate, shorter time to stable heart rate and respiration, and higher left ventricular ejection fraction compared to the control group. There was no significant difference in the incidence of adverse reactions between the milrinone group and the control group. However, more rigorous studies with larger sample sizes are needed to confirm these findings. [Extracted from the article]